RxDoctor Payments Data

Zaheer Ahmed, MD

Neurology · Chesterfield, MONPI 1558328401

Payments from drug & device makers

$20,094in general payments, 2019–2025

Across 1,216 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Supernus Pharmaceuticals, Inc.$1K
  • Pfizer$1K
  • Novartis$871
  • Teva Pharmaceuticals USA, Inc.$755
  • UCB, Inc.$554
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$19,98299%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)406$6,385
Supernus Pharmaceuticals, Inc.43$1,370
Pfizer172$1,196
Novartis57$871
Teva Pharmaceuticals USA, Inc.41$755
UCB, Inc.26$554
Lilly USA, LLC29$554
Amgen25$508
Lundbeck LLC20$481
CSL Behring14$369
Eisai Inc.18$341
Upsher-smith Laboratories LLC16$333
Sunovion Pharmaceuticals Inc.21$308
Sanofi14$287
EMD Serono, Inc.18$285
Amneal Pharmaceuticals LLC13$253
Medtronic(2 entities)12$251
Biohaven Pharmaceuticals, Inc.18$247
Abbott11$242
Argenx US, Inc.10$239
Bristol Myers Squibb13$235
Bausch Health US, LLC19$226
Jazz Pharmaceuticals Inc.6$218
SK Life Science, Inc.11$214
AstraZeneca(2 entities)13$214
Biogen10$200
Neurelis, Inc.10$184
GE HealthCare9$180
Grifols USA, LLC9$168
Johnson & Johnson8$156
Tanabe Pharma America, Inc.8$150
Biohaven Pharmaceutical Holding Company Ltd.14$139
Takeda Pharmaceuticals U.S.A., Inc.4$130
Boston Scientific4$119
Avion Pharmaceuticals6$103
Adamas Pharmaceuticals, Inc.6$88
Acadia Pharmaceuticals Inc5$87
Neurocrine Biosciences, Inc.4$87
Catalyst Pharmaceuticals, Inc.4$83
Ipsen Biopharmaceuticals, Inc5$81
Arbor Pharmaceuticals, Inc.5$78
Banner Life Sciences, LLC4$72
Genentech USA, Inc.5$71
MDD US Operations, LLC3$71
E.r. Squibb & Sons, L.L.C.4$66
Microtransponder, Inc.2$65
Aquestive Therapeutics, Inc.1$62
Vanda Pharmaceuticals Inc.2$58
Zyla Life Sciences, Inc.4$53
Tersera Therapeutics LLC2$50
Alnylam Pharmaceuticals Inc.3$49
Avanir Pharmaceuticals, Inc.2$45
Aprecia Pharmaceuticals, LLC3$43
Akcea Therapeutics, Inc.2$41
Sumitomo Pharma America, Inc.2$40
Axsome Therapeutics, Inc.1$34
Acorda Therapeutics, Inc2$31
Currax Pharmaceuticals LLC2$27
Inspire Medical Systems, Inc.1$26
Assertio Therapeutics, Inc.2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,094 in reported general payments places this provider in the 75th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$199,049
Medicare patients
749
Services billed
7,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$106,750
Aimovig AutoinjectorErenumab-Aooe92$98,572
QuliptaAtogepant44$50,595
Nurtec OdtRimegepant Sulfate40$50,072
UbrelvyUbrogepant21$47,005
RytaryCarbidopa/Levodopa30$41,382
GlatopaGlatiramer Acetate12$29,520
Emgality PenGalcanezumab-Gnlm35$26,328
Gabapentin740$17,792
KeppraLevetiracetam16$17,376
BotoxOnabotulinumtoxina13$16,621
Ajovy AutoinjectorFremanezumab-Vfrm17$14,028
Memantine Hcl439$12,186
Carbidopa-LevodopaCarbidopa/Levodopa330$11,346
Lacosamide63$11,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox$6,385$114,22078 claims
Grifols USA, LLCGamunex-C$168$106,75014 claims
PfizerNurtec Odt, Dilantin$1,196$56,45466 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$253$47,43585 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$1,370$4,00211 claims
Upsher-smith Laboratories LLCTopiramate$333$2,350123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 381 neurology providers in Missouri.

Other neurology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →